With 10 vaccine candidates now in phase three trials, one expert predicts another million people worldwide could die within three to six months.
One of those vaccine candidates is produced by Novavax. Dr. Gregory Glenn, head of research and development for Novavax, tells NPR he's not concerned about politics tainting the vaccine approval process.
We're working on an upcoming episode about pandemic precautions and we want to hear from you. Fill out the form on this page and we may follow up on your response.